stella
beta
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma — Stella
Recruiting
Back to Lung Adenocarcinoma Stage III trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Shanghai Pulmonary Hospital, Shanghai, Shanghai Municipality
View full record on ClinicalTrials.gov